Immunomodulatory properties are attributed to apoptotic cells. These properties have been used to modulate allogeneic immune responses in experimental transplantation settings. In independent studies, apoptotic cell infusion has been shown to favor hematopoietic cell engraftment, to increase heart graft survival and to delay the lethal onset of graft-versus-host disease (GVHD). The goal of this review was to discuss how apoptotic cell infusion interferes with graft rejection or host rejection (i.e., GVHD) and to focus on the potential mediators or "perpetuators" involved in apoptotic cell-induced immunomodulation. Particular emphasis on apoptotic cell phagocytosis, TGF-β secretion and regulatory T cell induction was performed.
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Stimulating "naturally" immunosuppressive molecules (i.e., TGF-β) or immunomodulatory cells ("alternatively-activated" macrophages, certain DC subsets or regulatory T cells) in a physiological manner by using apoptotic cell infusion can be a promising way to induce tolerance.
Although the use of non specific immunosuppressive drugs has significantly reduced the incidence of acute graft rejection, the benefits of such therapies on chronic rejection and overall long-term graft survival are uncertain. Persistent excessive immunosuppression after therapeutic approaches of this type is associated with considerable long-term toxicity including increased incidence of cancers, infectious complications as well as metabolic diseases (e.g., diabetes, atherosclerosis, etc). Immunomodulatory approaches allowing for increased specificity are therefore needed. Cell-based therapy is one way of achieving tolerance to donor antigens. The use of donor apoptotic cell infusion has been proposed as an "alternative" cell-based therapy approach to induce tolerance. The mediators or "perpetuators" involved in the immunomodulatory properties of apoptotic cells are discussed in this review.
Immunomodulatory properties of apoptotic cells
Immunomodulatory properties are attributed to apoptotic cells. This is due to apoptotic cells themselves (1, 2) or to cells phagocyting apoptotic cells (3, 4) . Professional phagocytes, such as macrophages (3) or certain dendritic cells (DC) subsets (4), quickly capture apoptotic bodies, thereby preventing both the release of harmful products from dying cells turning to necrosis and the associated inflammatory responses. Several mechanisms have been described to explain the immunomodulatory effects of apoptotic cells (5) . Engulfment of apoptotic cells inhibits proinflammatory cytokine production by blocking NF-κB activation in phagocyting cells (6) . Apoptotic cell uptake by phagocytes blocks also their production of the type 1 cytokine IL-12 (7) as well as the Th17-related cytokines, IL-17 and IL-23 (8) .
Moreover, apoptotic neutrophils and T cells may prevent inflammatory cell recruitment by sequestering chemokines (2) . In addition, apoptotic cell death is frequently associated with 
Use of apoptotic cell infusion in transplantation settings
Physiological mechanisms that maintain immune homeostasis and self-tolerance have been exploited for a long time to induce tolerance to allografts. This is why the inhibitory effects of apoptotic cell infusion have been used to modulate alloreactive responses in experimental transplantation models (17) (18) (19) (20) (21) [ Table 1 ]. In hematopoietic cell (HC) transplantation, i.v.
apoptotic cell infusion favors allogeneic HC engraftment (17) , delays the onset of lethal acute GVHD (18) and prevents the anti-donor humoral response (19) . In solid organ transplantation models, donor apoptotic cell infusion increases heart graft survival (20, 21) whatever the timing of infusion: 7 days before heart transplantation (19) (as previously done with donor specific blood transfusion) or 7 days after (20) . The timing of apoptotic cell infusion does not seem to be a critical factor in the interference of alloreactive immune responses. The next questions to address are how i.v. apoptotic cell infusion may interfere with alloreactive responses and by which mediators (and mechanisms) the immunomodulatory effects are propagated?
Mediators involved in the immunomodulatory effects of apoptotic cells
All three studies performed in transplantation settings (18, 20, 21) shared the requirement for apoptotic cell phagocytosis in a limited area (the spleen), but the nature of phagocytes differed. Two studies (18, 20) identified recipient macrophages as critical for the apoptotic cell infusion-induced immunomodulatory effects. This was attested by macrophage depletion before apoptotic cell infusion using gadolinium chloride (20) Macrophages rapidly degrade internalized antigens without presenting them, while DC exhibit limited lysosomal degradation capacity (22) favoring donor alloantigen presentation. A restricted donor-specific effect related to donor apoptotic cell phagocytosis by DC and subsequent donor alloantigen presentation may account for prolonged heart graft survival (21) . Donor apoptotic cell-loaded DC may migrate to the thymus to perform alloantigenspecific T cell deletion. In HC transplantation, apoptotic cell phagocytosis by macrophages (18) may lead to a non-specific anti-inflammatory effect associated with TGF-β production (19, see below), independent of donor alloantigen presentation. Indeed, HC engraftment is favored whatever the origin (donor/recipient/other) of apoptotic cells (17, 19) . The subsequent anti-inflammatory effect related to TGF-β secretion may neutralize host immune cells to allow HC engraftment and reduce the cytokine storm responsible for GVHD initiation.
To reconcile data obtained from different transplantation models (17, 19) , an alternative explanation would be that both macrophages and DC are necessary for apoptotic cellinduced engraftment. In this scenario, anti-inflammatory cytokines produced by macrophages after phagocytosis (i.e., TGF-β) may induce DC to present alloantigens from apoptotic cells in an inefficient manner. This may explain why donor apoptotic cell-loaded DC infusion after heart transplantation induces an initial proliferation of alloreactive T cells followed by their deletion (21) . This hypothesis is currently under investigation. to be demonstrated. Interleukin-10 dependent-Treg induction after infusion of syngeneic splenocytes rendered apoptotic by photopheresis has also been reported (24) . Interestingly, Treg induction after random blood product transfusion has been reported previously (25) and nonspecific immunomodulatory effects of preoperative blood product transfusion has been proposed to be related to the presence of apoptotic leukocytes in stored blood products (26) .
Treg induction after blood cell apoptosis -a frequent phenomenon, mimicked by i.v. infusion of apoptotic cells may constitute an additional mechanism to prevent autoimmunity that could be used in transplantation.
Conclusion
In conclusion, we propose infusing apoptotic cells to interfere with graft rejection or host rejection (GVHD). This approach permits to stimulate "naturally" immunosuppressive molecule production (i.e., TGF-β) or to activate immunomodulatory cells (such as Treg and particular DC or macrophage subsets) in a physiological manner. Exploiting such mechanisms may facilitate the induction of immunological tolerance to transplants. However, before the possible application of such therapy to clinical transplantation, several obstacles need to be overcome, including the interactions of such an approach with immunosuppressive regimens. In the future, i.v. donor apoptotic cells may become a welldefined cell therapy product and a substitute for the blood products formerly used in transfusion practice to prolong graft survival. Indeed, similitude exists between donor-specific blood transfusion and i.v. apoptotic leukocyte infusion including induction of Treg (25) or of TGF-β production (27) . Some biological effects of transfusion may be related to the presence of apoptotic leukocytes in blood products (26) . This idea of using the immunomodulatory properties of apoptotic cells in cell-based therapy is moving forward, since such an approach has also been proposed to increase cardiac muscle repair (28) . Days post-graft TGF-β mRNA/GAPDH mRNA expression *
